Perrigo (NYSE:PRGO) Stock Price Up 5.7% – Still a Buy?

Perrigo Company plc (NYSE:PRGO)’s stock price was up 5.7% during mid-day trading on Thursday . The stock traded as high as $10.71 and last traded at $10.73. 164,647 shares were traded during mid-day trading, a decline of 95% from the average daily volume of 3,196,631 shares. The stock had previously closed at $10.15.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Weiss Ratings raised shares of Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 15th. Zacks Research upgraded shares of Perrigo from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. One analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $19.33.

Perrigo Stock Up 7.7%

The company has a debt-to-equity ratio of 1.45, a current ratio of 2.72 and a quick ratio of 1.59. The company has a market capitalization of $1.51 billion, a PE ratio of -0.83, a P/E/G ratio of 1.18 and a beta of 0.51. The business has a 50-day moving average of $10.69 and a 200 day moving average of $11.95.

Perrigo (NYSE:PRGO) last posted its earnings results on Wednesday, May 6th. The company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. Perrigo had a negative net margin of 43.50% and a positive return on equity of 9.96%. The firm had revenue of $841.80 million during the quarter, compared to analyst estimates of $1.04 billion. During the same period last year, the firm posted $0.60 earnings per share. Perrigo’s revenue for the quarter was down 7.2% compared to the same quarter last year. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Equities research analysts predict that Perrigo Company plc will post 2.11 earnings per share for the current year.

Perrigo Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 16th. Stockholders of record on Friday, May 29th were issued a $0.29 dividend. The ex-dividend date was Friday, May 29th. This represents a $1.16 dividend on an annualized basis and a dividend yield of 10.6%. Perrigo’s payout ratio is -8.85%.

Hedge Funds Weigh In On Perrigo

Large investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD boosted its position in shares of Perrigo by 3.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 17,574,227 shares of the company’s stock valued at $244,634,000 after buying an additional 653,925 shares during the period. Vanguard Group Inc. grew its position in shares of Perrigo by 7.9% during the 4th quarter. Vanguard Group Inc. now owns 14,983,369 shares of the company’s stock worth $208,568,000 after buying an additional 1,101,154 shares in the last quarter. Fuller & Thaler Asset Management Inc. increased its position in Perrigo by 291.9% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 7,824,759 shares of the company’s stock valued at $108,921,000 after purchasing an additional 5,828,076 shares during the period. State Street Corp increased its holdings in Perrigo by 9.5% during the second quarter. State Street Corp now owns 7,340,323 shares of the company’s stock valued at $196,134,000 after buying an additional 637,678 shares during the period. Finally, Thompson Siegel & Walmsley LLC raised its position in shares of Perrigo by 28.4% in the 4th quarter. Thompson Siegel & Walmsley LLC now owns 4,658,601 shares of the company’s stock worth $64,848,000 after acquiring an additional 1,029,770 shares in the last quarter. 95.91% of the stock is owned by hedge funds and other institutional investors.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.